康艾注射液对结直肠癌肝转移介入术后肝功能的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Kang′ai Injection on liver function in patients with colorectal cancer liver metastasis after transcatheter arterial chemoembolization (TACE).Methods A total of 46 patients with colorectal cancer liver metastasis who were admitted to our hospital from January 2014 to December 2016 were selected as the research subjects.They were divided into control group and study group according to the order of admission, with 23 cases in each group.Both groups were treated with TACE, patients in the control group received regular liver protection therapy alone, while patients in the study group received Kang′ai Injection on the basis of regular liver protection therapy.The treatment effect, clinical main symptoms, serum liver function indicators (alanine transaminase [ALT], aspartate transaminase [AST], total bilirubin [TBil], total bile acid [TBA]and albumin [ALB]), tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigen 19-9 [CA19-9]and alpha-fetoprotein [AFP]), and Karnofsky (KPS) scores before and after treatment in the two groups were compared.Results There were no significant differences in the incidence rates of pain in the liver area, fever and jaundice before treatment between the two groups of patients (P＞0.05).The incidence rates of pain in the liver area, fever and jaundice of the two groups after treatment were lower than those before treatment, and those in the study group were lower than those in the control group, the differences were statistically significant (P＜0.05).After treatment, the levels of ALT, AST, TBil, and TBA in the study group were lower than those in the control group, and the ALB level was higher than that in the control group, the differences were statistically significant (P＜0.05).There were no significant differences in the levels of tumor markers between the two groups after treatment (P＞0.05).The total effective rate of treatment in the study group (60.9%) was higher than that in the control group (52.2%), and the difference was statistically significant (P＜0.05).There was no significant difference in KPS score between the two groups after treatment (P＞0.05).Conclusion Kang′ai Injection has a better protection of liver function, can be used as an adjunct to prevent colorectal cancer liver metastasis after TACE from liver damage, and can also indirectly improve the overall therapeutic effect of colorectal cancer liver metastasis.

Key words： Colorectal cancer liver metastasis；Transcatheter arterial chemoenbolization；Kang&prime ai Injection；Liver function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xiao-wei
	ZHOU Si-wei
	MA Zhen-nan▲

Cite this article:

ZHANG Xiao-wei,ZHOU Si-wei,MA Zhen-nan▲. Effect of Kang′ai Injection on liver function after colorectal cancer liver metastasis intervention[J]. 中国当代医药, 2020, 27(11): 76-80.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I11/76

[1]	Margonis GA，Sasaki K，Kim Y，et al.Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases[J].J Gastrointest Surg，2016，20（11）：1821-1829.
[2]	中华医学会外科学分会胃肠外科学组，中华医学会外科学分会结直肠肛门外科学组，中国抗癌协会大肠癌专业委员会.结直肠癌肝转移诊断和综合治疗指南（V2013）[J].中国实用外科杂志，2013，33（8）：635-644.
[3]	葛宝健，张健飞，蔡琳，等.结肠癌肝转移的腔隙学研究[J].医学与哲学，2015，36（10B）：75-77.
[4]	Jones RP，Malik HZ，Fenwick SW，et al.PARAGON Ⅱ-A single arm multicentre phase Ⅱstudy of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer[J].Eur J Surg Oncol，2016，42（12）：1866-1872.
[5]	林建军，金昌男，曾金雄，等.康艾注射液联合射频消融治疗原发性肝癌临床观察[J].光明中医，2009，24（10）：1887-1889.
[6]	Poultsides GA，Servais EL，Saltz LB，et al.Outcome of primary tumor in patients with synchronous stage Ⅳcolorectal cancer receiving combination chemotherapy without surgery as initial treatment[J].J Clin Oncol，2009，27（20）：3379-3384.
[7]	Nozawa H，Ishihara S，Kawai K，et al.Conversion to resection in patients receiving systemic chemotherapy for unresectable and/or metastatic colorectal cancer-predictive factors and prognosis[J].Clin Colorectal Cancer，2018，17（1）：91-97.
[8]	Stillwell AP，Buettner PG，Ho YH.Meta-analysis of survival of patients with stage Ⅳcolorectal cancer managed with surgical resection versus chemotherapy alone[J].World J Surg，2010，34（4）：797-807.
[9]	Wei N，Zhang B，Wang Y，et al.Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis[J].Clin Transl Oncol，2019，21：443-450.
[10]	叶涛，王耀辉，夏景林，等.肝动脉化疗栓塞治疗结直肠癌肝转移的疗效和预后影响因素[J].中华肿瘤杂志，2012，34（9）：706-709.
[11]	陈文政，柳青峰，王燕庆.结直肠癌肝转移个体化综合性治疗的研究进展[J].大连医科大学学报，2016，38（1）：97-100，102.
[12]	Jung SW，Kim DS，Yu YD，et al.Risk factors for cancer recurrence or death within 6 months after liver resection in patients withcolorectal cancer liver metastasis[J].Ann Surg Treat Res，2016，90（5）：257-264.
[13]	孜那提·努尔太，成芳，孟涛.179例结直肠癌肝转移初始不可切除的转化治疗疗效及预后分析[J].临床肿瘤学杂志，2019，24（05）：418-422.
[14]	刘希琴，周松.康艾注射液治疗肿瘤临床研究进展[J].医药导报，2009，28（5）：625-626.
[15]	蒋益兰，李东方，曾柏荣，等.康艾注射液对老年晚期消化系统肿瘤患者的疗效和安全性[J].中国老年学杂志，2018，38（12）：2889-2892.
[18]	肖敏，刘瑛，田武生，等.康艾注射液联合化疗对中晚期结直肠癌免疫功能及中医症候的影响[J].当代医学，2017，23（7）：9-12.
[16]	Wan YM，Li YH，Xu ZY，et al.The Effect of transarterial chemoembolization in combination with Kang′ai Injection on patients with intermediate stage hepatocellular carcinoma：a prospective study[J].Integr Cancer Ther，2018，17（2）：477-485.
[17]	Chen Y，Zhong MZ，Lu M.Randomized controlled clinical trial of kang′ai injection in gastrointestinal cancerchemotherapy patients[J].Zhongguo Zhong Yao Za Zhi，2012，37（19）：2990-2992.